Currently out of the existing stock ratings of Kaveri Pohlman, 11 are a BUY (84.62%), 2 are a HOLD (15.38%).

Kaveri Pohlman

Work Performance Price Targets & Ratings Chart

Analyst Kaveri Pohlman works at BTIG with a stock forecast success ratio of 18.75% fulfilled within 40.63 days on average.

Kaveri Pohlman’s has documented 24 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NUVB, Nuvation Bio at 26-Mar-2024.

Wall Street Analyst Kaveri Pohlman

Analyst best performing recommendations are on CMPI (CHECKMATE PHARMACEUTICALS).
The best stock recommendation documented was for CMPI (CHECKMATE PHARMACEUTICALS) at 3/30/2022. The price target of $9 was fulfilled within 20 days with a profit of $5.78 (179.5%) receiving and performance score of 89.75.

Average potential price target upside

CTMX CytomX Therapeutics CMPI Checkmate Pharmaceuticals MGNX MacroGenics ONCS OncoSec Medical MRSN Mersana Therapeutics BCAB Bioatla  GMAB Genmab AS NUVB Nuvation Bio RCUS Arcus Biosciences REPL Replimune Group

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

3

$0.94 (45.63%)

2

5 months 4 days ago

3/8 (37.5%)

$1.75 (140.00%)

119

Hold

3.3

$1.24 (60.19%)

3.19

5 months 4 days ago

1/9 (11.11%)

$2.05 (164.00%)

56

Hold

2

$-0.06 (-2.91%)

4

1 years 15 days ago

1/6 (16.67%)

$0.48 (31.58%)

336

Sell

12

1 years 5 months 2 days ago

0/2 (0%)

$7.4 (160.87%)

Hold

1.75

$-0.31 (-15.05%)

1.5

1 years 8 months 7 days ago

2/5 (40%)

$0.09 (5.42%)

59

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Kaveri Pohlman is most bullish on?

Potential upside of $5.88 has been obtained for REPL (REPLIMUNE GROUP)

Which stock is Kaveri Pohlman is most reserved on?

Potential downside of $1.77 has been obtained for NUVB (NUVATION BIO)

What Year was the first public recommendation made by Kaveri Pohlman?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?